Providing additional options for CRISPR-based research
The last thing you should have to worry about in product development is choosing the right CRISPR nuclease. You need licensing access to any field or application you wish to work on.
Inscripta developed and released the MAD7 nuclease to the global research community in 2017 under a broad technology access program to democratize access to CRISPR and promote its widespread adoption in both academic and commercial settings.
Inscripta now offers a portfolio of MADzymeTM nucleases under an expanded, non-exclusive licensing program including several MAD variants with improved properties
such as expanded PAM sites, altered activity profiles and higher fidelity. Please contact us below to learn more.